{"id":"NCT02726581","sponsor":"Bristol-Myers Squibb","briefTitle":"An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma","officialTitle":"An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-10","primaryCompletion":"2022-03-09","completion":"2022-03-09","firstPosted":"2016-04-01","resultsPosted":"2023-03-27","lastUpdate":"2023-03-27"},"enrollment":170,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558"]},{"type":"BIOLOGICAL","name":"Elotuzumab","otherNames":["BMS-901608"]},{"type":"DRUG","name":"Pomalidomide","otherNames":[]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"Investigational Arm","type":"EXPERIMENTAL"},{"label":"Control Arm","type":"ACTIVE_COMPARATOR"},{"label":"Exploratory Arm","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either:\n\nGroup 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone.\n\nEnrollment is closed for all groups.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"From randomization to the date of the first documented tumor progression or death due to any cause, whichever occurred first (Up to approximately 64 month)","effectByArm":[{"arm":"Arm A: N-Pd","deltaMin":8.38,"sd":null},{"arm":"Arm B: Pd","deltaMin":7.33,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":121,"countries":["United States","Austria","Canada","Czechia","Denmark","Germany","Greece","Israel","Italy","Norway","Portugal","Puerto Rico","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":72},"commonTop":["Fatigue","Anaemia","Neutropenia","Diarrhoea","Upper respiratory tract infection"]}}